The Effects of Nafamostat Mesilate on a Bleeding Risk as an Anticoagulant During Use as a Continuous Renal Replacement Therapy: Systematic Review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: In the past, the pharmaceutical drug heparin was mostly used as the anticoagulant for continuous renal replacement therapy (CRRT), but the duration time is long to have the risk of a bleeding adverse effect, and in that case the drug therapy Nafamostat mesilate was utilized instead, as it is more safe in this case, with a short half-life and is increasing in use to permit lower concerns for bleeding incidents. However, there are insufficient number of large-scale studies on the comparison of Nafamostat mesilate and heparin. Methods: In this study, a systematic review are used to compare the bleeding risk of Nafamostat mesilate and Heparin, as subjected to patients and procedures for measuring risks performed with a CRRT, and the filter life span is to be evaluated as well in this patients. Results: As a result of literature review search, a total of 6 studies were included in systematic review. The reducing risk of bleeding and filter life span was analyzed. The retrospective cohort studies confirm that Nafamostat mesilate is less at risk of bleeding than heparin. And a cohort study confirms that Nafamostat mesilate is longer filter lifespan than heparin and randomized controlled trial studies show that Nafamostat mesilate is longer filter lifespan than not using the anticoagulants. Conclusion: Nafamostat mesilate is considered to be a good therapeutic option because it has a longer filter life span as well as the advantage of reducing bleeding.
Abstract
Objectives: In the past, the pharmaceutical drug heparin was mostly used as the anticoagulant for continuous renal replacement therapy (CRRT), but the duration time is long to have the risk of a bleeding adverse effect, and in that case the drug therapy Nafamostat mesilate was utilized instead, as it is more safe in this case, with a short half-life and is increasing in use to permit lower concerns for bleeding incidents. However, there are insufficient number of large-scale studies on the comparison of Nafamostat mesilate and heparin. Methods: In this study, a systematic review are used to compare the bleeding risk of Nafamostat mesilate and Heparin, as subjected to patients and procedures for measuring risks performed with a CRRT, and the filter life span is to be evaluated as well in this patients. Results: As a result of literature review search, a total of 6 studies were included in systematic review. The reducing risk of bleeding and filter life span was analyzed. The retrospective cohort studies confirm that Nafamostat mesilate is less at risk of bleeding than heparin. And a cohort study confirms that Nafamostat mesilate is longer filter lifespan than heparin and randomized controlled trial studies show that Nafamostat mesilate is longer filter lifespan than not using the anticoagulants. Conclusion: Nafamostat mesilate is considered to be a good therapeutic option because it has a longer filter life span as well as the advantage of reducing bleeding.
참고문헌 (19)
- Schetz M, "Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view", Intensive Care Med, 15, pp.349~357 (1989)
- Tolwani AJ, "Anticoagulation for continuous renal replacement therapy", Semin Dial, 22, pp.141~145 (2009)
- Van de Wetering J, "Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage", J Am Soc Nephrol, 7, pp.145~150
- Reeves JH, "A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration", Crit Care Med, 27, pp.2224~2228 (1999)
- Journois D, "Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration", Ann Fr Anesth Reanim, 9, pp.331~337 (1990)
- Van der Voort PH, "Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation", Blood Purif, 23, pp.175~180 (2005)
- 김현철, "출혈 위험이 있는 혈액투석 환자에서 국소 항응고제 Futhan의 효과 - 다기관 공동 연구", Kidney Research and Clinical Practice, 23(6), pp.920~926 (2004), 대한신장학회
- Okada H, "Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate", Nephrol Dial Transplant, 7, pp.980~ (1992)
- 박인일, "출혈 위험성이 있는 환자에서 지속적 정정맥 여과술 시행 시 생리식염수 주사와 nafamostat mesilate의 항응고 효과의 전향적 비교 연구", Kidney Research and Clinical Practice, 28(3), pp.205~210 (2009), 대한신장학회
- Kinnunen EM, "Clinical significance and determinants of the universal definition of perioperative bleeding classification in patients undergoing coronary artery bypass surgery", J Thorac Cardiovasc Surg, 148, pp.1640~1646 (2014)
- Fealy N, "Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units", Crit Care Resusc, 17, pp.83~91 (2015)
- Baek NN, "The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding", Ren Fail, 34, pp.279~285 (2012)
- 이승호, "지속적 신대체요법을 시행 받은 환자들의 치료 결과와 예후", Kidney Research and Clinical Practice, 29(4), pp.434~440 (2010), 대한신장학회
- Makino S, "Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy", Int J Artif Organs, 39, pp.16~21 (2016)
- Hwang SD, "Nafamostat mesilate for anticoagulation in continuous renal replacement therapy", Int J Artif Organs, 36, pp.208~216 (2013)
- Uchino S, "Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators", Intensive Care Med, 33, pp.1563~1570 (2007)
- Ohtake Y, "Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration", Contrib Nephrol, 93, pp.215~217 (1991)
- Lee YK, "Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study", PLoS One, 9, pp.e108737~ (2014)
- Choi JY, "Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial", Medicine (Baltimore), 94, pp.e2392~ (2015)